Filing Details

Accession Number:
0000950170-24-107458
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-17 18:20:32
Reporting Period:
2024-09-17
Accepted Time:
2024-09-17 18:20:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815442 Kymera Therapeutics Inc. KYMR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744425 Pamela Esposito C/O Kymera Therapeutics, Inc.
500 North Beacon Street, 4Th Floor
Watertown MA 02472
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-17 8,500 $29.55 8,500 No 4 M Direct
Common Stock Acquisiton 2024-09-17 5,000 $14.18 13,500 No 4 M Direct
Common Stock Disposition 2024-09-17 6,350 $47.75 7,150 No 4 S Direct
Common Stock Disposition 2024-09-17 7,150 $48.75 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-09-17 8,500 $0.00 8,500 $29.55
Common Stock Stock Option (Right to Buy) Disposition 2024-09-17 5,000 $0.00 5,000 $14.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
31,627 2030-09-03 No 4 M Direct
7,000 2032-06-14 No 4 M Direct
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.26 to $48.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $49.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The shares underlying this stock option are fully vested and exercisable.